DICE Therapeutics
Liliana Moura Massis has a diverse and extensive work experience in the fields of immunology, microbiology, and clinical laboratory assistance. Liliana began their career as a Clinical Laboratory Assistant at Sancet Medicina Diagnóstica in 1998. Liliana then went on to work at various prestigious institutions, including Harvard Medical School, where they served as a Visiting Postdoctoral Scholar in 2010. Liliana also worked as a Postdoctoral Fellow at Faculdade de Medicina de Ribeirão Preto / USP from 2014 to 2016.
In 2016, Liliana joined Stanford University as a Research Scientist in Microbiology and Immunology, where they worked until 2021. During this time, they gained significant expertise in their field. In addition, Liliana was involved in the Grupo Mulheres do Brasil as a Volunteer starting in 2019.
Recently, Liliana joined DiCE Molecules in 2021, where they initially held the role of Scientist and was later promoted to Scientist II, specializing in Immunology. With their extensive work experience and expertise, Liliana has made valuable contributions to the field of immunology throughout their career.
Liliana Moura Massis obtained their Bachelor's degree in Biomedical Sciences from Universidade de Mogi das Cruzes, where they studied from 1998 to 2001. Liliana then pursued their PhD in Microbiology at USP - Universidade de São Paulo, completing their studies from 2002 to 2007. Additionally, in 2005, they spent a brief period as a Visiting Doctoral Student at the University of Oklahoma, focusing on Microbiology and Molecular Biology.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.